S
Sporos Bioventures
A private biopharmaceutical company that aims to transform the drug development process by focusing on key mechanisms and targets of disease to accelerate drug discovery
About Sporos Bioventures
Sporos Bioventures, LLC is a private biotechnology company dedicated to revolutionizing the drug development process in the oncology sector. The company focuses on creating targeted cancer treatments by leveraging a deep understanding of cancer biology, genetic vulnerabilities, and tumor microenvironment interactions. Sporos Bioventures operates through its affiliate portfolio companies, including Sporos BioDiscovery and Asylia Therapeutics, and holds equity interests in several biopharma entities such as Tvardi Therapeutics. The company’s business model is centered around research and development (R&D), utilizing a framework that generates critical biological insights into tumor-specific vulnerabilities. This approach aims to design potent and targeted therapies that enhance patient outcomes and quality of life. Sporos Bioventures makes money through equity stakes in its portfolio companies and the development of proprietary preclinical assets. The company serves clients in the biopharma and healthcare sectors, focusing on delivering innovative cancer treatments efficiently and cost-effectively.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 57.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 4 companies, latest Jun 2021
- Capital deployed
- $121M
- Preferred round
- SERIES A
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2021 | $38M | $152M | Undisclosed | — |
Growth signals
Latest recorded traffic for Sporos Bioventures is 130 monthly website visits, down 74% over the last three months. Sporos Bioventures's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Stellanova TherapeuticsHouston, United StatesDeveloping the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment
$62Mvaluation
Tvardi TherapeuticsHouston, United StatesA clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases
$296Mvaluation
Asylia TherapeuticsHouston, United StatesCommitted to transforming scientific advances into medicines for cancer & autoimmune diseases
$58Mvaluation
Nirogy TherapeuticsNatick, United StatesDeveloping novel small molecules to target cellular transporters
$66Mvaluation
Sporos Bioventures in the Houston ecosystem
The Sporos Bioventures office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sporos Bioventures on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sporos Bioventures’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






